Breast cancer hormone receptor status in Egypt: are we asking the questions that matter most?
Drs. Dey, Soliman and colleagues have produced a valuable breast cancer study based on an analysis of the Gharbiah population-based cancer registry in Tanta, Egypt, a region located 90 kilometers north of Cairo in the Nile Delta Region . Founded in 1998 through the Middle East Cancer Consortium (MECC), the Gharbiah registry represents an important new information source regarding cancer demographics in a major Middle Eastern population. This is a well executed study which presents some interesting data on hormone receptor status among Egyptian breast cancer cases. The investigators compared breast cancer incidence among patients in urban (62%) vs. rural (38%) areas and looked for differences in the biological features of breast cancers diagnosed between 2001 and 2006. They observed that among 3,673 cases, the incidence of estrogen receptor positive (ER+) breast cancers was 2–4 times higher in urban areas than in rural areas. Why would ER+ breast cancer be more commonly diagnosed in...
KeywordsBreast Cancer Urban Region Hormone Receptor Status Adjuvant Tamoxifen Seek Health Care
- 1.Dey S, Soliman AS, Hablas A, Seifeldin IA, Ismail K, Ramadan M et al. (2009) Urban-rural differences in breast cancer incidence by hormone receptor status across 6 years in Egypt. Breast Cancer Res Treat. doi: 10.1007/s10549-009-0427-9
- 4.Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P et al (2007) Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute’s Surveillance, Epidemiology, and End Results database. Cancer 110(4):876–884CrossRefPubMedGoogle Scholar
- 8.Early Breast Cancer Trialists’ Collaborative Group (2001) Tamoxifen for early breast cancer. Cochrane Database Syst Rev (1):CD000486. doi: 10.1002/14651858.CD000486